Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments-Reference-Cited by-同舟云学术

Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments

Published:2006-11 Issue:4 Volume:3 Page:421-427
ISSN:1741-0541
Container-title:Personalized Medicine
language:en
Short-container-title:Personalized Medicine

Author:

Issa Amalia M¹,Todd Weiss L¹,Tufail Waqas¹,Phillips Kathryn A²,Van Bebber Stephanie L²

Affiliation:

1. The Methodist Hospital and University of Houston, Program in Personalized Medicine & Targeted Therapeutics and the Abramson Center for the Future of Health, 300 Technology Building, T2–309, Houston, TX 77204–4021, USA.

2. University of California, Department of Clinical Pharmacy, School of Pharmacy, San Francisco, 521 Parnassus Avenue, C-152 Box 0622, University of California, San Francisco, CA 94143–0622, USA

Abstract

BiDil® (hydralazine and isosorbide dinitrate) represents an interesting application of personalized medicine – the first pharmaceutical specifically approved by a regulatory agency, the US FDA, for an indication in a particular population based on race as a surrogate phenotypic marker, without a companion genomic diagnostic directed at measuring drug responsiveness. The focus of this paper is to use BiDil as a case study of a personalized medicine application and evaluate its clinical and policy-relevant characteristics as an illustrative example of the usefulness of the Evaluation Data for Assessing Personalized Medicine Translation (EDAPT) evidence base.

Publisher

Future Medicine Ltd

Subject

Pharmacology,Molecular Medicine,General Medicine

Link

https://www.futuremedicine.com/doi/pdf/10.2217/17410541.3.4.421

Reference53 articles.

1. Gleevec™ for the Treatment of Chronic Myelogenous Leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status

2. Moving towards individualized medicine with pharmacogenomics

3. The AmpliChip™ CYP450 Genotyping Test

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Capacity building for assessing new technologies: approaches to examining personalized medicine in practice;Personalized Medicine;2010-07

2. Innovation in personalized medicine: BiDil® as a case study for integrating clinical and policy developments;Personalized Medicine;2006-11